Rigel Pharmaceuticals宣布,该公司针对低风险骨髓增生异常综合征(MDS)患者开展的R289药物1B期临床研究的剂量扩展阶段已成功招募首位患者入组。这一里程碑标志着该项临床试验进入了关键的新阶段,为进一步评估R289在治疗低风险MDS患者中的安全性和有效性奠定了基础。
Rigel Pharmaceuticals宣布,该公司针对低风险骨髓增生异常综合征(MDS)患者开展的R289药物1B期临床研究的剂量扩展阶段已成功招募首位患者入组。这一里程碑标志着该项临床试验进入了关键的新阶段,为进一步评估R289在治疗低风险MDS患者中的安全性和有效性奠定了基础。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.